| Literature DB >> 24677135 |
Li-Li Sun1, Jian Wang1, Zhi-Juan Zhao1, Ning Liu2, Ai-Lian Wang1, Hua-Yan Ren1, Fan Yang1, Ke-Xin Diao1, Wei-Neng Fu3, En-Hua Wan1, Xiao-Yi Mi1.
Abstract
TRAF2 promotes cancer cell survival, proliferation and metastasis through the NF-κB pathway by directly interacting with various TNF recepors. However, the molecular mechanism of TRAF2 dysregulation in breast cancer remains to be elucidated. In the present study, miR-502-5p was predicted as a potential regulator of TRAF2. miR-502-5p was significantly downregulated in breast cancer tissues when compared to the level in paired normal breast tissues. The breast cancer cell lines including MCF-7 and MDA-MB-231 expressed a lower level of miR-502-5p when compared to the level in the non-malignant breast epithelial cell line MCF-10A. In vitro, miR-502-5p enhanced early apoptosis and inhibited proliferation of breast cancer cells. Luciferase reporter assay results showed that miR-502-5p could bind to the 3'-untranslated region of the TRAF2 gene, thus, exerting an inhibitory effect on TRAF2. Furthermore, silencing of TRAF2 exhibited effects similar to those of exogenous miR‑502-5p, while overexpression of TRAF2 partially abrogated miR-502-5p-mediated suppression in breast cancer cells. In conclusion, miR-502-5p may act as a tumor-suppressor gene by targeting oncogenic TRAF2 in breast cancer and, therefore, may be a potential diagnostic and anticancer therapeutic marker for breast cancer.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24677135 DOI: 10.3892/or.2014.3105
Source DB: PubMed Journal: Oncol Rep ISSN: 1021-335X Impact factor: 3.906